PROM1 and glioblastoma: Zeppernick et al. 38 also found that both the proportion of CD133+ cells and their topological organization using immunohistochemitry (IHC), were prognostic factors for adverse, progression-free survival and that the proportion of CD133+ cells was an independent risk factor for GBM regrowth.